XyloCor Therapeutics, a gene therapy company based in Malvern that is developing new treatments for cardiovascular diseases, has raised $17 million in its series A financing round, writes John George for the Philadelphia Business Journal.
The cardiovascular angiogenic, XC001, is also being developed by XyloCor as a one-time gene therapy for patients. It is a treatment-resistant refractory angina or for patients with refractory angina who have no other treatment options.
“XC001 has the potential to provide new hope for patients who suffer from this chronic and debilitating disease,” said Al Gianchetti, president and CEO of XyloCor. “We are grateful for the support and confidence demonstrated by our investors.”
Meanwhile, XyloCor’s secondary product, XC002, is being examined for its potential to regenerate cardiac tissue in patients who suffered cardiac damage from heart attacks. It is currently in the discovery stage.
Read more about XyloCor Therapeutics in the Philadelphia Business Journal here.